# A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

> **NCT03495323** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 17 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** LY3300054
- **DRUG:** Prexasertib

## Key facts

- **NCT ID:** NCT03495323
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-16
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-02-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495323, "A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03495323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*